Dal, Mehmet SinanKarakus, AbdullahEkmen, Mehmet OnderAyyildiz, Orhan2024-04-242024-04-2420162038-83222038-8330https://doi.org/10.4081/hr.2016.6409https://hdl.handle.net/11468/19508Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder characterized by intravascular hemolysis. Real-world experience of PNH management is largely unreported. A retrospective analysis was undertaken based on medical records from six patients with PNH [two with aplastic anemia (AA)] treated at our center, Dicle University, Turkey. Diagnosis was based on granulocyte PNH clones, ranging from 93% to 66%. All patients had symptoms consistent with PNH. One patient was managed adequately with supportive measures only. Five were treated with the complement inhibitor eculizumab. Follow-up data (< 1 year) were available in four cases (the fifth had received only three infusions by final follow-up). Hemoglobin level in these four patients increased from 4.1-7.2 g/dL to 8.3-13.0 g/dL. Lactate dehydrogenase, a marker for hemolysis, decreased profoundly in the two non-AA patients, with more minor improvements in the two AA patients. Weakness and fatigue improved in all eculizumab-treated patients. Four of the five treated patients became transfusion independent, including the patient given only three infusions. In the remaining case, a patient with AA, transfusion requirement decreased, and abdominal pain and dysphagia resolved. No adverse events occurred. PNH can be successfully managed in routine practice.eninfo:eu-repo/semantics/openAccessHemolysisAplastic AnemiaParoxysmal Nocturnal HemoglobinuriaEculizumabArticle81WOS:0003763526000062-s2.0-849620288472710398110.4081/hr.2016.6409Q4N/A